Figure 2.
Simplified model of PARK2 dysfunction in cancer and familial PD. In PD, mutational inactivation of PARK2 is sufficient to raise cyclin E levels, which helps bring about neurotoxicity. In cancer cells, PARK2 mutations occur in conjunction with other oncogenic alterations, resulting in increased tumor cell growth.